Compare NFE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | ACRS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 311.0M |
| IPO Year | 2018 | 2015 |
| Metric | NFE | ACRS |
|---|---|---|
| Price | $0.50 | $4.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.50 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 5.2M | 1.2M |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | $1,683,000.00 |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.34 |
| 52 Week High | $4.96 | $5.15 |
| Indicator | NFE | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 46.70 |
| Support Level | N/A | $4.15 |
| Resistance Level | $0.77 | $4.62 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 1.74 | 25.00 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.